These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 22170099)

  • 21. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2.
    Cao C; Shinohara ET; Subhawong TK; Geng L; Kim KW; Albert JM; Hallahan DE; Lu B
    Mol Cancer Ther; 2006 Feb; 5(2):411-7. PubMed ID: 16505116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
    Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
    J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
    Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
    Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.
    Ohnstad HO; Paulsen EB; Noordhuis P; Berg M; Lothe RA; Vassilev LT; Myklebost O
    BMC Cancer; 2011 May; 11():211:1-11. PubMed ID: 21624110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
    Xie X; He G; Siddik ZH
    Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
    Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L
    J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nutlin-3a selects for cells harbouring TP53 mutations.
    Kucab JE; Hollstein M; Arlt VM; Phillips DH
    Int J Cancer; 2017 Feb; 140(4):877-887. PubMed ID: 27813088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53.
    Manfé V; Biskup E; Johansen P; Kamstrup MR; Krejsgaard TF; Morling N; Wulf HC; Gniadecki R
    J Invest Dermatol; 2012 May; 132(5):1487-96. PubMed ID: 22377766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression.
    Blaheta RA; Daher FH; Michaelis M; Hasenberg C; Weich EM; Jonas D; Kotchetkov R; Doerr HW; Cinatl J
    BMC Cancer; 2006 Dec; 6():294. PubMed ID: 17181871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.
    Van Maerken T; Rihani A; Dreidax D; De Clercq S; Yigit N; Marine JC; Westermann F; De Paepe A; Vandesompele J; Speleman F
    Mol Cancer Ther; 2011 Jun; 10(6):983-93. PubMed ID: 21460101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual-channel surface plasmon resonance monitoring of intracellular levels of the p53-MDM2 complex and caspase-3 induced by MDM2 antagonist Nutlin-3.
    Wu L; Hu Y; He Y; Xia Y; Lu H; Cao Z; Yi X; Wang J
    Analyst; 2019 Jul; 144(13):3959-3966. PubMed ID: 31134974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model.
    Kotchetkov R; Cinatl J; Blaheta R; Vogel JU; Karaskova J; Squire J; Hernáiz Driever P; Klingebiel T; Cinatl J
    Int J Cancer; 2003 Mar; 104(1):36-43. PubMed ID: 12532417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression.
    Kotchetkov R; Driever PH; Cinatl J; Michaelis M; Karaskova J; Blaheta R; Squire JA; Von Deimling A; Moog J; Cinatl J
    Int J Oncol; 2005 Oct; 27(4):1029-37. PubMed ID: 16142320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype.
    Zhong B; Shingyoji M; Hanazono M; Nguyễn TT; Morinaga T; Tada Y; Shimada H; Hiroshima K; Tagawa M
    Apoptosis; 2020 Aug; 25(7-8):535-547. PubMed ID: 32468177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
    Zauli G; Voltan R; Bosco R; Melloni E; Marmiroli S; Rigolin GM; Cuneo A; Secchiero P
    Clin Cancer Res; 2011 Feb; 17(4):762-70. PubMed ID: 21106726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
    Zauli G; Celeghini C; Melloni E; Voltan R; Ongari M; Tiribelli M; di Iasio MG; Lanza F; Secchiero P
    Haematologica; 2012 Nov; 97(11):1722-30. PubMed ID: 22689683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.
    Gu L; Zhu N; Findley HW; Zhou M
    Leukemia; 2008 Apr; 22(4):730-9. PubMed ID: 18273046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
    Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
    Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.